Free Trial
NASDAQ:WVE

WAVE Life Sciences Q3 2025 Earnings Report

WAVE Life Sciences logo
$7.89 +0.10 (+1.28%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$8.04 +0.15 (+1.84%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

WAVE Life Sciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.30
Beat/Miss
N/A
One Year Ago EPS
N/A

WAVE Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$9.85 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

WAVE Life Sciences Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 11, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

WAVE Life Sciences Earnings Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
Wave Life Sciences (WVE) Receives a Buy from Leerink Partners
See More WAVE Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like WAVE Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on WAVE Life Sciences and other key companies, straight to your email.

About WAVE Life Sciences

WAVE Life Sciences (NASDAQ:WVE) is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications. Several assets are advancing through preclinical research and clinical trials, and WAVE collaborates with biopharmaceutical partners to co-develop selected candidates and expand the reach of its technology into new disease areas.

WAVE’s research and development activities are anchored in its laboratories in Cambridge, Massachusetts, where multidisciplinary teams of chemists, biologists and clinical scientists work to translate novel oligonucleotide designs into development candidates. The company also maintains strategic collaborations and research partnerships in North America and Asia, aiming to accelerate global access to its therapies and support regulatory filings in multiple jurisdictions.

Founded in 2015, WAVE Life Sciences has built a leadership team with deep expertise in RNA biology, medicinal chemistry and drug development. The company continues to refine its stereopure oligonucleotide platform to address delivery challenges, improve pharmacokinetics and expand its pipeline across a broad range of genetic and rare diseases.

View WAVE Life Sciences Profile

More Earnings Resources from MarketBeat